QuidelOrtho Corporation (QDEL) Stock
QDEL Key Statistics
About QuidelOrtho Corporation
QuidelOrtho Corporation specializes in the creation and production of diagnostic testing solutions, addressing a wide array of healthcare testing demands. The company operates through distinct business units. Its Labs division provides clinical chemistry and immunoassay instruments and tests designed to analyze bodily fluids and proteins, aiding in health assessment, patient management, and tracking disease progression. The Transfusion Medicine unit focuses on ensuring blood safety and compatibility by offering immunohematology and infectious disease screening tests for blood and plasma. For rapid results in various clinical environments, the Point-of-Care segment delivers quick diagnostic tests. Additionally, the Molecular Diagnostics arm develops advanced polymerase chain reaction thermocyclers, analyzers, and amplification systems. QuidelOrtho distributes its offerings both directly to end-users and through an extensive network of distributors. These products are utilized by professionals in settings such as medical offices, hospitals, clinical and reference laboratories, urgent care centers, universities, retail clinics, pharmacies, wellness screening centers, and blood/donor banks, as well as for individual, non-professional, and over-the-counter applications. Founded in 1979 and based in San Diego, California, the company maintains a global footprint, including operations across North America, Europe, the Middle East, Africa, and China.
CEO: Brian J. Blaser. Company website
QDEL — Frequently Asked Questions
What is the QDEL stock price today?
QuidelOrtho Corporation (QDEL) trades at $10.62, down 4.24% on the day, as of Sep 20, 2026 15:01 UTC.
What is QuidelOrtho Corporation's market cap?
QuidelOrtho Corporation has a market capitalisation of $724.19M, calculated from the live QDEL share price and shares outstanding.
What is the P/E ratio of QDEL?
QDEL has no meaningful price-to-earnings ratio: QuidelOrtho Corporation lost $15.44 per share over the last twelve months, and a P/E is only defined on positive earnings.
How much revenue does QuidelOrtho Corporation make?
QuidelOrtho Corporation generated revenue of $2.67B over the trailing twelve months, which puts the stock at 0.27 times sales.
What is the 52-week range for QDEL?
QDEL has traded between $9.92 and $35.58 over the past 52 weeks, and the last price is 70.1% below that high.
Is QuidelOrtho Corporation profitable?
No. QuidelOrtho Corporation is loss-making, with a net margin of -39.20% over the trailing twelve months.
What is the analyst price target for QDEL?
Wall Street analysts rate QDEL Hold, with an average price target of $12.25, 15.3% above the current price.
What sector is QuidelOrtho Corporation in?
QuidelOrtho Corporation is classified under the Healthcare sector and the Medical - Specialties industry, and is domiciled in US.
Who is the CEO of QuidelOrtho Corporation?
Brian J. Blaser is the chief executive of QuidelOrtho Corporation, which employs 6,500 people.
Where can I track QDEL in real time?
QFI Terminal shows QDEL with live charts, full financials, the options chain with gamma exposure, institutional ownership and analyst ratings on one screen. The free plan has no time limit and asks for no card.
See QDEL live in QFI Terminal
Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.
Open QDEL in Terminal See plans